Drugs / polio vaccine
polio vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04639375 | Nov 2020 → Jun 2021 | COVID-19 | E-MO Biology Inc | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-08-07 | Sinovac Biotech Co., Ltd | Results SINOVAC科兴灭活脊灰疫苗与其他疫苗同时接种安全有效 sinovac.com ↗
研究结果表明，无论是单独接种还是与其他疫苗同时接种， SINOVAC科兴的sIPV大规模应用于儿童基础免疫和加强免疫时，均具有良好的安全性和免疫原性。 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-30 | Evaxion Biotech A/S | Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress evaxion.ai ↗ |
| 2025-07-22 | Codagenix, Inc | Codagenix Awarded PATH Subcontract to Develop Stabilized Novel Oral Polio Vaccine Candidates codagenix.com ↗ |
| 2025-03-25 | SK Bioscience Co., Ltd. | SK bioscience and IVI Announce the 2025 Recipients of the ‘Park MahnHoon Award’ Four Honorees Recognized for Contributions to Polio Vaccine Development and Global Immunization Efforts skbioscience.com ↗ |
| 2024-08-07 | Sinovac Biotech Co., Ltd | SINOVAC科兴灭活脊灰疫苗与其他疫苗同时接种安全有效 sinovac.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | polio vaccine | “All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States” NCT04639375 ↗ |
| Known as | IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04639375 ↗ |
| Known as | poliovirus vaccine | “poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States” NCT04639375 ↗ |
| Modality | Vaccine | “poliovirus vaccine (IPV)” NCT04639375 ↗ |